Targeting protein kinase C-alpha (PKC-α) in cancer with the phosphorothioate antisense oligonucleotide aprinocarsen

被引：20
|
作者：
Lahn, M [1 ]
Sundell, K
Moore, S
机构：
[1] Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA
[2] Volt Vendor Associate, Indianapolis, IN USA
来源：
THERAPEUTIC OLIGONUCLEOTIDES: ANTISENSE, RNAI, TRIPLE-HELIX, GENE REPAIR, ENHANCER DECOYS, CPG AND DNA CHIPS | 2003年 / 1002卷
关键词：
protein kinase C-alpha; cancer; antisense oligonucleotide; targeted therapies;
D O I：
10.1196/annals.1281.029
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Antisense oligonucleotides (ASOs) offer a novel pharmacological platform to develop highly specific drugs. As shown by the clinical development of aprinocarsen, an ASO directed against protein kinase Galpha (PKC-alpha), this platform has made a remarkable advance from the bench to the bedside. This review summarizes the rationale of the early development of aprinocarsen and current clinical experience.
引用
收藏
页码：263 / 270
页数：8
相关论文
共 50 条
  • [1] The role of protein kinase C-alpha (PKC-α) in cancer and its modulation by the novel PWC-α-specific inhibitor aprinocarsen
    Hanauske, AR
    Sundell, K
    Lahn, M
    CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (16) : 1923 - 1936
  • [2] The role of protein kinase C-alpha (PKC-α) in melanoma
    Lahn, MM
    Sundell, KL
    MELANOMA RESEARCH, 2004, 14 (02) : 85 - 89
  • [3] The role of protein kinase C-alpha (PKC-α) in malignancies of the gastrointestinal tract
    Lahn, M
    Paterson, BM
    Sundell, K
    Ma, D
    EUROPEAN JOURNAL OF CANCER, 2004, 40 (01) : 10 - 20
  • [4] Inactivation of protein kinase C-alpha (PKC-α) by S-glutathiolation:: A novel mechanism of PKC regulation.
    Ward, NE
    O'Brian, CA
    FASEB JOURNAL, 2002, 16 (04): : A154 - A154
  • [5] Protein Kinase C-Alpha (PKC-α) knockdown by targeted siRNA inhibits melanoma cell migration
    Byers, H. R.
    Boissel, S. J.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2007, 127 : S152 - S152
  • [6] Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-sinall-cell lung cancer
    Paz-Ares, L
    Douillard, JY
    Koralewski, P
    Manegold, C
    Smit, EF
    Reyes, JM
    Chang, GC
    John, WJ
    Peterson, PM
    Obasaju, CK
    Lahn, M
    Gandara, DR
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (09) : 1428 - 1434
  • [7] Enhanced activity of an antisense oligonucleotide targeting murine protein kinase C-alpha by the incorporation of 2'-O-propyl modifications
    McKay, RA
    Cummins, LL
    Graham, MJ
    Lesnik, EA
    Owens, SR
    Winniman, M
    Dean, NM
    NUCLEIC ACIDS RESEARCH, 1996, 24 (03) : 411 - 417
  • [8] Antisense against protein kinase C-alpha mRNA sense for cancer therapy?
    Stewart, A
    MOLECULAR MEDICINE TODAY, 1997, 3 (08): : 324 - 324
  • [9] INHIBITION OF PROTEIN-KINASE C-ALPHA EXPRESSION IN MICE AFTER SYSTEMIC ADMINISTRATION OF PHOSPHOROTHIOATE ANTISENSE OLIGODEOXYNUCLEOTIDES
    DEAN, NM
    MCKAY, R
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (24) : 11762 - 11766
  • [10] Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide
    Yazaki, T
    Ahmad, S
    Chahlavi, A
    ZylberKatz, E
    Dean, NM
    Rabkin, SD
    Martuza, RL
    Glazer, RI
    MOLECULAR PHARMACOLOGY, 1996, 50 (02) : 236 - 242
12345